Dandekar Atul 4

What Happened
Atul Dandekar, Maze Therapeutics (MAZE) Chief Strategy & Business Officer, exercised 7,500 stock options and immediately sold 7,500 shares on April 29, 2026. The exercise acquisition cost reported was $78,150 (7,500 shares × $10.42). The open-market sale generated gross proceeds of $190,299 (7,500 shares at a weighted average $25.37), yielding a pre-tax difference of about $112,149.

Key Details

• Transaction date: 2026-04-29; Form 4 filed: 2026-05-01 (timely filing).
• Exercise (code M): 7,500 shares acquired at $10.42 each — total $78,150. The option was fully vested (vested March 17, 2025).
• Sale (code S): 7,500 shares sold at a weighted average price of $25.37 — total proceeds $190,299. Sales prices in the block ranged from $25.08 to $25.77 per share.
• A separate line shows a disposition of 7,500 derivative units at $0, reflecting the derivative conversion/settlement associated with the exercise.
• Sale executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
• Shares owned after the transactions are not specified in the provided excerpt of the filing.

Context
This was an exercise-and-sell (often called a cashless or immediate-sale) transaction: the insider exercised vested options and sold the resulting shares under a pre-established 10b5-1 plan. Such trades are typically pre-authorized and can be routine; they do not alone indicate management's forward-looking view of the company.